New price cuts in Spain will "strangle" pharmaceutical industry
This article was originally published in Scrip
Executive Summary
The pharmaceutical industry in Spain is shocked and appalled at new austerity measures in Spain that will introduce yet more price cuts, obligatory prescribing by active ingredient, a reorganisation of the reference pricing system and new ways of determining which drugs to reimburse. They will further risk the future of local companies and SMEs, says Farmaindustria, which represents the R&D-based pharmaceutical industry.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.